JARID2 and neoplasm: Analyzed by the Kaplan-Meier method with log-rank test, high tumor JARID2 expression were found to be associated with lower DFS (1-, 3- and 5-year DFS: 63.2%, 35.5%, 17.9% vs. 87.2%, 68.1%, 37.5%, P = 0.001; Figure 2B1), lower OS (1-, 3- and 5-year OS: 78.1%, 63.0%, 25.1% vs. 89.4%, 80.9%, 48.2%, P = 0.002; Figure 2B2) and a significantly higher early recurrence rate (recurrence within 2 years: 47.8% vs. 21.3%, P = 0.003; Figure 2B3) than patients with low JARID2 expression.